176 related articles for article (PubMed ID: 21212150)
1. Pseudomonas aeruginosa fosfomycin resistance mechanisms affect non-inherited fluoroquinolone tolerance.
De Groote VN; Fauvart M; Kint CI; Verstraeten N; Jans A; Cornelis P; Michiels J
J Med Microbiol; 2011 Mar; 60(Pt 3):329-336. PubMed ID: 21212150
[TBL] [Abstract][Full Text] [Related]
2. The glycerol-3-phosphate permease GlpT is the only fosfomycin transporter in Pseudomonas aeruginosa.
Castañeda-García A; Rodríguez-Rojas A; Guelfo JR; Blázquez J
J Bacteriol; 2009 Nov; 191(22):6968-74. PubMed ID: 19734311
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Fosfomycin Resistance Protein FosA by Phosphonoformate (Foscarnet) in Multidrug-Resistant Gram-Negative Pathogens.
Ito R; Tomich AD; McElheny CL; Mettus RT; Sluis-Cremer N; Doi Y
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993329
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effect of fosfomycin and fluoroquinolones against Pseudomonas aeruginosa growing in a biofilm.
Mikuniya T; Kato Y; Kariyama R; Monden K; Hikida M; Kumon H
Acta Med Okayama; 2005 Oct; 59(5):209-16. PubMed ID: 16286954
[TBL] [Abstract][Full Text] [Related]
5. Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal
Ito R; Mustapha MM; Tomich AD; Callaghan JD; McElheny CL; Mettus RT; Shanks RMQ; Sluis-Cremer N; Doi Y
mBio; 2017 Aug; 8(4):. PubMed ID: 28851843
[TBL] [Abstract][Full Text] [Related]
6. The action of fosfomycin on the growth of Pseudomonas aeruginosa.
Hardisson C; Llaneza J
Chemotherapy; 1977; 23 Suppl 1():37-44. PubMed ID: 401719
[TBL] [Abstract][Full Text] [Related]
7. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.
Walsh CC; Landersdorfer CB; McIntosh MP; Peleg AY; Hirsch EB; Kirkpatrick CM; Bergen PJ
J Antimicrob Chemother; 2016 Aug; 71(8):2218-29. PubMed ID: 27118778
[TBL] [Abstract][Full Text] [Related]
8. Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa.
Dupont P; Hocquet D; Jeannot K; Chavanet P; Plésiat P
J Antimicrob Chemother; 2005 Apr; 55(4):518-22. PubMed ID: 15722391
[TBL] [Abstract][Full Text] [Related]
9. In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa.
Walsh CC; McIntosh MP; Peleg AY; Kirkpatrick CM; Bergen PJ
J Antimicrob Chemother; 2015 Nov; 70(11):3042-50. PubMed ID: 26209311
[TBL] [Abstract][Full Text] [Related]
10. Identification of a second two-component signal transduction system that controls fosfomycin tolerance and glycerol-3-phosphate uptake.
Kurabayashi K; Hirakawa Y; Tanimoto K; Tomita H; Hirakawa H
J Bacteriol; 2015 Mar; 197(5):861-71. PubMed ID: 25512306
[TBL] [Abstract][Full Text] [Related]
11. Role of fosfomycin in a synergistic combination with ofloxacin against Pseudomonas aeruginosa growing in a biofilm.
Monden K; Ando E; Iida M; Kumon H
J Infect Chemother; 2002 Sep; 8(3):218-26. PubMed ID: 12373484
[TBL] [Abstract][Full Text] [Related]
12. Small-Molecule Inhibitor of FosA Expands Fosfomycin Activity to Multidrug-Resistant Gram-Negative Pathogens.
Tomich AD; Klontz EH; Deredge D; Barnard JP; McElheny CL; Eshbach ML; Weisz OA; Wintrode P; Doi Y; Sundberg EJ; Sluis-Cremer N
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642934
[TBL] [Abstract][Full Text] [Related]
13. Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa.
Muramatsu H; Horii T; Takeshita A; Hashimoto H; Maekawa M
Chemotherapy; 2005 May; 51(2-3):70-5. PubMed ID: 15870499
[TBL] [Abstract][Full Text] [Related]
14. [Assessment of 2 automated microdilution techniques compared to an agar dilution method in determining sensitivity to fosfomycin in strains of carbapenem-resistant Pseudomonas aeruginosa].
Gil-Romero Y; Regodón-Domínguez M; Wilhelmi de Cal I; López-Fabal F; Gómez-Garcés JL
Enferm Infecc Microbiol Clin; 2016; 34(7):406-8. PubMed ID: 26620604
[TBL] [Abstract][Full Text] [Related]
15. Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections.
Rodríguez-Rojas A; Maciá MD; Couce A; Gómez C; Castañeda-García A; Oliver A; Blázquez J
PLoS One; 2010 Apr; 5(4):e10193. PubMed ID: 20419114
[TBL] [Abstract][Full Text] [Related]
16. A putative de-N-acetylase of the PIG-L superfamily affects fluoroquinolone tolerance in Pseudomonas aeruginosa.
Liebens V; Defraine V; Van der Leyden A; De Groote VN; Fierro C; Beullens S; Verstraeten N; Kint C; Jans A; Frangipani E; Visca P; Marchal K; Versées W; Fauvart M; Michiels J
Pathog Dis; 2014 Jun; 71(1):39-54. PubMed ID: 24692291
[TBL] [Abstract][Full Text] [Related]
17. The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model.
Drusano GL; Neely MN; Yamada WM; Duncanson B; Brown D; Maynard M; Vicchiarelli M; Louie A
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249700
[TBL] [Abstract][Full Text] [Related]
18. In vitro investigations on the action fosfomycin alone and in combination with other antibiotics on Pseudomonas aeruginosa and Serratia marcescens.
Ullmann U; Lindemann B
Arzneimittelforschung; 1980; 30(8):1247-9. PubMed ID: 6776966
[TBL] [Abstract][Full Text] [Related]
19. A multidrug efflux pump inhibitor reduces fluoroquinolone resistance in Pseudomonas aeruginosa isolates.
Coban AY; Ekinci B; Durupinar B
Chemotherapy; 2004 Apr; 50(1):22-6. PubMed ID: 15084801
[TBL] [Abstract][Full Text] [Related]
20. Assessing Pseudomonas aeruginosa Persister/antibiotic tolerant cells.
Hazan R; Maura D; Que YA; Rahme LG
Methods Mol Biol; 2014; 1149():699-707. PubMed ID: 24818944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
